From initial discovery to FDA approval, the average drug development timeline is 10 to 15 years and costs an estimated 1 to 2.6 billion dollars. Here is how that time is distributed, and why patient participation in clinical trials is the single biggest lever for accelerating it.
The Full Timeline
Preclinical research: 3–6 years. Before any human testing, a drug is evaluated in laboratory and animal models for basic safety and biological activity.
Phase I: 1–2 years. First-in-human safety testing in 10–80 participants. Approximately 70% of drugs advance past Phase I.
Phase II: 2–3 years. Effectiveness testing in 100–300 patients. Approximately 33% of drugs that enter Phase II make it to Phase III.
Phase III: 3–5 years. Large-scale confirmatory trials, the phase where patient enrollment is most critical. Approximately 50–70% of Phase III programs result in an FDA submission.
FDA Review: 6–12 months. Standard review takes about 12 months; priority review (for serious conditions) takes 6 months.
Expedited Pathways
The FDA offers several programs to accelerate development: – Fast Track designation, more frequent FDA interaction and rolling review – Breakthrough Therapy designation, intensive guidance for drugs showing substantial improvement – Accelerated Approval, approval based on a surrogate endpoint – Priority Review, 6-month review for serious conditions
Why Your Participation Matters
Phase III clinical trials, the largest and most time-consuming phase, are where patient enrollment is the critical bottleneck. Studies that enroll quickly complete faster, shortening the development timeline. Every participant contributes directly to the speed at which effective treatments reach patients.